Profile data is unavailable for this security.
About the company
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
- Revenue in USD (TTM)8.78k
- Net income in USD-32.44m
- Incorporated2014
- Employees57.00
- LocationEyenovia Inc295 Madison Ave Ste 2400NEW YORK 10017United StatesUSA
- Phone+1 (813) 766-9539
- Fax+1 (302) 636-5454
- Websitehttps://eyenovia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 40.85m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 41.06m | 32.00 | -- | 2.45 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
Immuneering Corp | 0.00 | -54.18m | 41.22m | 65.00 | -- | 0.5236 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Hcw Biologics Inc | 3.93m | -27.39m | 41.23m | 45.00 | -- | 4.72 | -- | 10.50 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
Dare Bioscience Inc | 2.82m | -28.87m | 41.45m | 23.00 | -- | -- | -- | 14.71 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
NKGen Biotech Inc | -100.00bn | -100.00bn | 41.56m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
Clene Inc. | 620.00k | -48.81m | 42.25m | 82.00 | -- | 9.91 | -- | 68.15 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
NextCure Inc | 0.00 | -63.73m | 43.08m | 82.00 | -- | 0.4339 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
Eyenovia Inc | 8.78k | -32.44m | 43.53m | 57.00 | -- | 21.06 | -- | 4,957.58 | -0.7448 | -0.7448 | 0.0002 | 0.0384 | 0.0003 | -- | 0.008 | 154.04 | -116.94 | -80.31 | -190.14 | -117.70 | 0.00 | -- | -369,519.70 | -680.95 | 0.6645 | -16.03 | 0.8914 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
Ocuphire Pharma Inc | 19.01m | -11.30m | 43.55m | 14.00 | -- | 0.915 | -- | 2.29 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
Aadi Bioscience Inc | 23.84m | -68.83m | 44.20m | 75.00 | -- | 0.4886 | -- | 1.85 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
Incannex Healthcare Inc | -100.00bn | -100.00bn | 44.92m | -- | -- | 3.18 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 45.06m | 134.00 | 3.81 | 0.1803 | 1.38 | 0.175 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
Gain Therapeutics Inc | 0.00 | -21.14m | 46.03m | 29.00 | -- | 5.32 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
Aligos Therapeutics Inc | 13.79m | -99.59m | 46.08m | 67.00 | -- | 0.7771 | -- | 3.34 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.73m | 3.43% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.46m | 2.88% |
Cowen & Co. LLCas of 31 Mar 2024 | 827.85k | 1.64% |
Geode Capital Management LLCas of 31 Mar 2024 | 693.34k | 1.37% |
Avenue Capital Management II LPas of 31 Mar 2024 | 547.81k | 1.08% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 519.28k | 1.03% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 261.08k | 0.52% |
BNP Paribas Financial Marketsas of 31 Mar 2024 | 219.61k | 0.43% |
Teachers Advisors LLCas of 31 Mar 2024 | 200.14k | 0.40% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 119.25k | 0.24% |